ABSTRACT

Background: Dermatomyositis (DM) is an idiopathic inflammatory myopathy with various cutaneous manifestations. There is a strong association between DM and malignancy with an estimated 5–7 fold increase in cancer incidence in DM patients compared to the general population. Dermatomyositis as a paraneoplastic manifestation has been reported in several malignancies notably ovarian, gastric, colon, cervical, pancreatic, and lung cancer but rarely in prostate cancer (Table 1).

Case Presentation: A 64-year-old male with a past medical history of hypertension, gout, and type II diabetes was admitted to the hospital following a mechanical fall after which he sustained shoulder and facial trauma. On further evaluation, the patient was found to have dysphagia, dysphonia, proximal upper extremity and lower extremity weakness, and rashes. The dysphagia began one month prior to presentation and the rashes appeared two months prior. Physical exam was notable for erythematous and scaly-dry skin in V-neck pattern, gottron papules, facial and periorbital erythema with scaly skin, periungual erythema, oropharyngeal salivary pooling, proximal bilateral upper and lower extremity weakness with intact distal extremity strength, and wasting of the bilateral quadriceps and hamstrings. Labs were notable for elevated creatine kinase (CPK) 296, positive Anti-p155/140 antibodies which are directed against transcription intermediate family-1 (TIF-1). Further workup with a computed tomography scan (CT) of the abdomen and pelvis revealed extensive pelvic and abdominal lymphadenopathy, centered in the pelvis, and therefore suspicious for either nodal metastasis from prostate adenocarcinoma versus lymphoma. A right inguinal lymph node biopsy was done and confirmed the diagnosis of metastatic adenocarcinoma of the prostatic primary. Staging workup via bone scan and MRI showed diffuse osseous metastases in the thoracolumbar spine (Figure 1). Consequently, the patient was started on Bicalutamide and Leuprolide as therapy for the underlying prostate cancer by the inpatient oncology team. The neurology service was consulted for the muscle weakness and were immediately concerned for dermatomyositis. Hence, they recommended empiric treatment with steroids which were initiated and a biopsy of the left deltoid muscle was obtained. Biopsy results revealed skeletal muscle with perifascicular atrophy and mild mixed inflammatory infiltrate, suggestive of DM (Figure 2). Hence, in the setting of the patient’s clinical presentation confirmed the diagnosis of DM likely...
paraneoplastic. The patient was started on intravenous immunoglobulins (IVIG) in addition to steroids for treatment of DM. The patient’s hospital course was complicated by worsening dysphagia necessitating percutaneous gastric tube placement (PEG), worsening dysphonia, as well as hypoxic respiratory failure requiring a brief intensive care unit admission and non-invasive positive pressure ventilation. The patient slowly regained his speech and his respiratory status improved. He was able to be discharged to a subacute rehab after 37 days of inpatient stay. The patient is still requiring a PEG tube for feeding but his dysphagia has significantly improved, and his rashes have almost resolved. His muscle strength is slowly recovering. He continues to get IVIG sessions and steroids as well as Leuprolide injections every three months for treatment of his metastatic prostate cancer. His prostate-specific antigen (PSA) a marker that is usually elevated in prostate cancer and was markedly elevated in this patient began to downtrend significantly which usually indicates a positive response to therapy.

Conclusion: This case illustrates the importance of screening for an underlying malignancy in any patient presenting with DM. Because of the rarity of DM physicians should maintain a high index of suspicion and screen for more cancers than only those reported to be commonly associated with DM. Cases have shown that systemic manifestations of paraneoplastic DM tend to improve following treatment of the underlying malignancy.

### Table 1

<table>
<thead>
<tr>
<th>AUTHORS</th>
<th>YEAR</th>
<th>AGE</th>
<th>SYMPTOMS AT PRESENTATION</th>
<th>CANCER DIAGNOSIS</th>
<th>TREATMENT</th>
<th>SYNDROME ONSET</th>
<th>COUNTRY</th>
<th>CLINICAL STATUS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hideyuki Minagawa et al.</td>
<td>2021</td>
<td>63</td>
<td>erythema on the skin, and muscle weakness with severe dysphagia appeared</td>
<td>Metastatic prostate adenocarcinoma with neuroendocrine differentiation.</td>
<td>High dose steroids and chemotherapy and androgen deprivation therapy</td>
<td>After prostate cancer diagnosis</td>
<td>Japan</td>
<td>improved</td>
</tr>
<tr>
<td>Hee Yeon Kim et al.</td>
<td>2009</td>
<td>73</td>
<td>cutaneous lesions and progressive symmetric proximal muscle weakness</td>
<td></td>
<td>systemic steroid, intravenous immunoglobulin and methotrexate.</td>
<td>After prostate cancer diagnosis</td>
<td>Korea</td>
<td>improved</td>
</tr>
<tr>
<td>Béla Tallai et al.</td>
<td>2006</td>
<td>57</td>
<td>Total immobility developed in a short period of time; Purple-coloured rashes developed on his hand and face. These were the so-called heliotrope rash, Gottron's papule</td>
<td>Prostate cancer</td>
<td>High-dose methylprednisolone; and prostatectomy</td>
<td>Preceded prostate cancer diagnosis</td>
<td>Hungary</td>
<td>improved</td>
</tr>
<tr>
<td>Charalampos Papagoras et al.</td>
<td>2018</td>
<td>59</td>
<td>recurrent facial swelling and redness, accompanied by worsening fatigue during the previous 3 months</td>
<td>Metastatic neuroendocrine prostate cancer</td>
<td></td>
<td>preceded cancer diagnosis</td>
<td>Greece</td>
<td>deceased</td>
</tr>
<tr>
<td>Paula Renaux Caratta et al.</td>
<td>2011</td>
<td>72</td>
<td>only classic skin findings, which progressed to vesiculobullous lesions, and, months later, to myopathy</td>
<td>Prostate adenoca</td>
<td>Systemic steroids and chemotherapy</td>
<td>Preceded cancer diagnosis</td>
<td>Brazil</td>
<td>improved</td>
</tr>
<tr>
<td>SHIN-ICHI ANSAI M.D. et al.</td>
<td>1996</td>
<td>74</td>
<td>Severe edema of the face and periorbital region, myalgias or extremities and dysphagia</td>
<td>Prostate adenoca</td>
<td>Systemic steroids</td>
<td>Preceded cancer diagnosis</td>
<td>Japan</td>
<td>deceased</td>
</tr>
<tr>
<td>J. V. JOSEPH et al.</td>
<td>2002</td>
<td>63</td>
<td>erythematous rash on the scalp, neck, upper chest, back, extensor aspect of the elbow and gluteal region. The patient also had purple plaques over the back of his hand</td>
<td>Metastatic prostate Ca</td>
<td>Hormonal ablative therapy and steroids</td>
<td>Preceded cancer diagnosis</td>
<td>Scotland</td>
<td>improved</td>
</tr>
<tr>
<td>Sekine Y et al.</td>
<td>2004</td>
<td>69</td>
<td>general fatigue, appetite loss and facial anthems</td>
<td>Metastatic prostate Ca</td>
<td>diethylstilbestrol phosphate and prednisolone</td>
<td>Preceded cancer diagnosis</td>
<td>Japan</td>
<td>deceased</td>
</tr>
<tr>
<td>COLIN J MOONEY et al.</td>
<td>2006</td>
<td>72</td>
<td>1-month history of weakness and dull aches in his shoulders and thighs bilaterally</td>
<td>Metastatic prostate Ca</td>
<td>androgen-deprivation therapy and steroids</td>
<td>Preceded cancer diagnosis</td>
<td>USA</td>
<td>improved</td>
</tr>
</tbody>
</table>
Figure 1 Multifocal enhancing osseous metastases involving the thoracolumbar. Spine without spinal cord compression.

Figure 2 This H and E stained skeletal muscle with perifascicular atrophy and mild mixed inflammatory infiltrate, suggestive of dermatomyositis(40X).
COMPETING INTERESTS
The authors have no competing interests to declare.

AUTHOR AFFILIATIONS

Iman Makki  
Mount Sinai Morningside-West Hospital Center, Icahn School of Medicine at Mount Sinai, New York, US

Binbin Zheng-Lin  
Mount Sinai Morningside-West Hospital Center, Icahn School of Medicine at Mount Sinai, New York, US

Clare Bryce  
Mount Sinai Hospital, Icahn School of Medicine at Mount Sinai, New York, NY, US

Sadhna Ahuja  
Mount Sinai Hospital, Icahn School of Medicine at Mount Sinai, New York, NY, US

Sridevi Rajeeve  
Mount Sinai Hospital, Icahn School of Medicine at Mount Sinai, New York, NY, US

Vaibhav Patel  
Mount Sinai Hospital, Icahn School of Medicine at Mount Sinai, New York, NY, US

TO CITE THIS ARTICLE:  

Submitted: 20 May 2021  
Accepted: 20 May 2021  
Published: 11 June 2021

COPYRIGHT:  
© 2021 The Author(s). This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International License (CC-BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. See http://creativecommons.org/licenses/by/4.0/.

Journal of Scientific Innovation in Medicine is a peer-reviewed open access journal published by Levy Library Press.